globenewswire.com · 2 jul

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees.

globenewswire.com · 29 jun

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28

zacks.com · 17 jun

DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?

Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.

benzinga.com · 12 jun

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP).

seekingalpha.com · 9 jun

Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

globenewswire.com · 2 jun

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on June 1, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

seekingalpha.com · 30 may

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

globenewswire.com · 26 may

Dianthus Therapeutics to Participate in Two Investor Conferences

NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in two investor conferences in June 2026.